Efficacy of the UK recombinant plague vaccine to protect against pneumonic plague. in the nonhuman primate, Macaca fascicularis {PRIVATE }

Transcription

1 Efficacy of the UK recombinant plague vaccine to protect against pneumonic plague in the nonhuman primate, Macaca fascicularis {PRIVATE } M.L.M. Pitt, D. Dyer, J. Hartings, K. Batey United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, Frederick, MD, , USA Research was conducted in compliance with the Animal Welfare Act and other Federal statutes and regulations relating to animals and experiments involving animals and adheres to principles stated in the Guide for the Care and Use of Laboratory Animals, National Research Council, The facility where this research was conducted is fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation. 1

2 Report Documentation Page Form Approved OMB No Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. 1. REPORT DATE 05 MAY REPORT TYPE N/A 3. DATES COVERED - 4. TITLE AND SUBTITLE Efficacy of the UK recombinant plague vaccine to protect against pneumonic plague in the nonhuman primate, Macaca fascicularis, USAMRIID Tech Report, A151 A.1 6. AUTHOR(S) Pitt, MLM Dyer, D Hartings, J Batey, K 5a. CONTRACT NUMBER 5b. GRANT NUMBER 5c. PROGRAM ELEMENT NUMBER 5d. PROJECT NUMBER 5e. TASK NUMBER 5f. WORK UNIT NUMBER 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 8. PERFORMING ORGANIZATION REPORT NUMBER A151 A.1 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR S ACRONYM(S) 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited 13. SUPPLEMENTARY NOTES 11. SPONSOR/MONITOR S REPORT NUMBER(S) 14. ABSTRACT The efficacy of the UK candidate plague vaccine was established in the cynomolgus macaque model for pneumonic plague. Animals were vaccinated intramuscularly on days 0 and 21 with either 40 µg F µg V or 80 µg F µg V in 0.5 ml 20% v/v Alhydrogel. They were challenged on day 60 with a lethal aerosol challenge (> 100 LD50) of CO 92 Y. pestis. All but one of the 19 vaccinated animals that were challenged survived. 15. SUBJECT TERMS Yersinia pestis, plague, F1-V fusion protein vaccine, CpG oligodeoxynucleotide antigens, efficacy, antibody response, aerosol challenge, laboratory animals, nonhuman primates 16. SECURITY CLASSIFICATION OF: 17. LIMITATION OF ABSTRACT SAR a. REPORT unclassified b. ABSTRACT unclassified c. THIS PAGE unclassified 18. NUMBER OF PAGES 43 19a. NAME OF RESPONSIBLE PERSON Standard Form 298 (Rev. 8-98) Prescribed by ANSI Std Z39-18

3 ABSTRACT The efficacy of the UK candidate plague vaccine was established in the cynomolgus macaque model for pneumonic plague. Animals were vaccinated intramuscularly on days 0 and 21 with either 40 µg F µg V or 80 µg F µg V in 0.5 ml 20%v/v Alhydrogel. They were challenged on day 60 with a lethal aerosol challenge (>100 LD 50 ) of CO 92 Y. pestis. All but one of the 19 vaccinated animals that were challenged survived. 2

4 1 INTRODUCTION Plague is an infection caused by the gram negative bacterium Yersinia pestis. Plague is an infection of small rodents and mammals - for example the rat. In the rodent population the disease exists in many forms covering a spectrum from acute to chronic illness. Plague has been responsible for a number of human epidemics - most notably the Black Death in the Middle Ages [1]. Transmission from rodent to man usually relies on a flea vector - although cases of pulmonary transmission have been described from household pets. Transmission to man by feeding fleas leads to the characteristic swelling of the draining lymph nodes, followed by a septicaemic illness. This presentation is the classical bubonic plague [2]. However, man-to-man transmission can occur via droplet nuclei spread by the coughing of patients with bubonic or septicaemic plague who have developed pulmonary lesions. There is a need for a less reactogenic, more protective and simpler to produce vaccine than the killed whole cell vaccine that was formerly produced as the USP plague vaccine. A new sub-unit vaccine for plague has been researched and developed at DSTL, Porton Down in the UK and this vaccine is now entering manufacture. The vaccine comprises the F1 and V sub-unit antigens of Yersinia pestis, which have been produced as purified recombinant proteins, derived from an E. coli host. The vaccine is formulated by adsorbing the F1 and V antigens to alhydrogel. The preclinical studies in mice have shown that the F1 + V sub-unit combination vaccine provides protection against an aerosolised challenge with Y. pestis [3-6]. Pharmaco-Toxicological Testing has been completed and shown 3

5 the vaccine to be safe in nonhuman primates (NHP) pharmacology studies measuring cardiovascular/respiratory parameters the vaccine has no adverse effects on the CNS in studies in mice. the vaccine has no toxic effects by acute toxicity, repeat dose testing, local tolerance testing & reproductive toxicity testing A Phase I Clinical Trial has demonstrated safety in a small number of human volunteers as required by the regulatory authorities. Normal Phase III studies are not possible when developing vaccine as a countermeasure against plague since, there is low risk of disease in the normal population and it would be unethical to challenge humans with live micro-organisms. Therefore there is a need to establish efficacy through the use of surrogate markers of protection as described in the FDA new rule (21 CFR Parts 314 and 601) and EMEA Guidance - CPMP/EWP/463/97. In essence animal models must be used as a means of establishing a relationship between protection in animals and humans. In light of this, Passive Transfer and a number of surrogate markers have been assessed in the Phase I Clinical Trial, as possible indicators of protection in Man. The above plus the need to give confidence to the customer that the plague vaccine will protect a Non-Human Primate and is thus likely to protect man mean that there is a requirement to assess the efficacy of the UK Recombinant Plague Vaccine in a NHP. To date several studies have been completed in the cynomolgus macaque which have demonstrated the F1+V vaccine to be immunogenic in the dose range of 5-40µg each of F1+V adsorbed to alhydrogel and schedule (day 0,21) intended for use in man. Passive transfer of sera or of IgG fractionated from the sera of vaccinated macaques into the 4

6 naïve mouse with subsequent challenge of the mouse has been carried out. This has shown that sera from vaccinated macaques are consistently protective against challenge from approximately day 28 of the immunization schedule through to week 53 after two immunizing doses of vaccine. Further, sera from the vaccinated macaques have been demonstrated to compete with a neutralizing monoclonal antibody for binding to the V antigen, in a competitive ELISA. The competitive binding data correlate with the passive transfer data for the macaque sera. Such data provide surrogate markers of efficacy for the F1+V vaccine in the cynomolgus macaque and the same set of assays for surrogate markers of efficacy have been applied to blood samples from individuals in Phase 1 clinical trials of the vaccine. In this study, cynomolgus macaques were vaccinated with formulated F1 + V vaccine using the same dose as in the Phase I clinical trial (40 µg each of F1 and V) and a higher dose of 80 µg each of F1 and V. The vaccination schedule (days 0 and 21) was the same as that used in the Phase I clinical trial. On day 60 the animals were challenged with a lethal aerosol challenge of Y. pestis. 5

7 2. MATERIALS AND METHODS 2.1 Experimental animals Cynomolgus macaques, males and females, 3 8 kg, were obtained from USAMRIID colony. 2.2 Telemetry Transducer Implants: Telemetry devices to measure temperature and activity (TA10TA-D70) were implanted subcutaneously in all cynomolgus macaques approximately 30 days prior to vaccination. These transducers were placed subcutaneously on the dorsum of the animal between the scapula, just off the midline at the level of the inferior edge of the scapular blade. 2.3 Vaccine Formulated vaccine containing 120 µg rf1 and 120 µg rv was received from Octoplus Holland. Placebo (diluent) was received from Baxter Vaccine Information 120/120 Microgram/0.5ml rv/rf1 containing 20% alhydrogel in saline. Batch Number 03D A Store at 5+/-3 o C. Retest Date 18/10/2003 Manufactured for DSTL 6

8 2.3.2 Diluent Batch # PC # Client Date 8/8/03 Temp 2 o C-8 o C 2.4 Preparation of Vaccine The vaccine was diluted to obtain the required vaccines dosages of 40/40µg and 80/80µg according to the following: 22 vials of formulated120/120 µg were mixed, opened and pooled to give approximately 12ml of vaccine suspension. 40/40 µg 4ml of vaccine + 8ml of Diluent. (volumes dispensed using a graduated pipette) 80/80 µg 7.5ml of vaccine ml of Diluent. (large volumes dispensed using a graduated pipette. Volumes under 1ml dispensed using a micropipette) Prepared vaccine dilutions were kept on ice throughout their period of use. 7

9 4 x 1ml volumes of each vaccine was aliquoted for shipment to Cylex. At Cylex they were assayed to determine the actual concentration of protein (data not available to USAMRIID) 2.5 Vaccination and Challenge Schedule Twenty-two Cynomolgus macaques (M. fascicularis) were divided into two groups of ten and one group of two. The 2 groups of 10 animals were vaccinated on days 0, and 21 with either 40 µg F µg V or 80 µg F µg V in 0.5 ml 20%v/v Alhydrogel, while the group of 2 received placebo, Saline/Alhydrogel, according to the same schedule. The animals were bled immediately prior to vaccination, and then on days 7, 14, 21, 28, 35, 42, 50 (10 ml) and 59 (20 ml). The blood was used to determine serum antibody levels to both F1 and V and assess cell mediated immunity. The day 59 sera will be used for passive transfer, IgG levels to F1 and V, competitive ELISAs and cell cytoxicity assays, and cell mediated immunity (data not available to USAMRIID). One vaccinated animal died prior to challenge of unrelated causes. The primary cause of death was determined to be acute cardiac decompensation secondary to chronic heart disease. The rest of the vaccinated animals were randomly divided into 2 challenge groups, with one control in each group, and were challenged on 2 consecutive days with approximately 126 ± 36 LD 50 of the F1 positive Y. pestis strain, CO Y. pestis challenge 8

10 Two days before the aerosol challenge, Tryptose blood agar base (TBAB) culture slants were inoculated with Y. pestis, Colorado 92. These were incubated for two days at o C. On the day of challenge, each slant culture was suspended in 1-2 ml of Heart Infusion Broth (HIB). Suspensions from the slants were pooled, vortexed for 10 sec. and the optical density (O.D.) of the suspension determined at 620 nm. (1 unit of optical density equates to a Y. pestis concentration of 10 9 cfu/ml.). The nonhuman primates were anesthetized with Telazol (6 mg/kg IM) for the aerosol challenge. Respiratory minute volumes were measured by whole body plethysmography using a Buxco Biosystem XA (Buxco Electronics, Sharon, CT), immediately before challenge. The animals were then immediately exposed to the bacterial aerosol, head-only, in a dynamic aerosol chamber controlled using the Automated Bioaerosol Exposure System. The aerosol (mass median aerosol diameter, 1.2 µm) was generated by a three-jet Collison nebulizer and sampled continuously by an all-glass impinger (AGI-30; Ace Glass, Inc., Vineland, N.J.). For each animal, the aerosol concentration of Y. pestis organisms was calculated by plating out dilutions of a sample from the AGI onto blood agar plates (Remel). The inhaled doses were then determined (express ed as LD 50 ). One aerosol LD 50 in the cynomolgus macaque is 400 organisms (MLM Pitt, unpublished observation). 2.7 Temperature Monitoring Temperature data was continuously collected hourly for one week prior to challenge and then for 14 days post challenge using Dataquest A.R.T. 2.3 software. 9

11 3. RESULTS Eight of the nine animals that were vaccinated with 40 µg F µg V in 0.5 ml 20%v/v Alhydrogel survived challenge. All 10 of the nonhuman primates that were vaccinated with 80 µg F µg V in 0.5 ml 20%v/v Alhydrogel survived challenge. The 2 controls (49470 and 99310) succumbed to pneumonic plague; one was euthanized 89 hr post exposure and the other died 86 hr post exposure (Figure 1 and 2). Both were bacteremic in the 24 hr prior to death. The vaccinated animal that died, developed a fever around 73 hr post-challenge, became bacteremic by 90 hr and died around 128 hr post-exposure. (Figure 3) Figure 1: # Temp. (oc) Time post-challenge (hr) 96 10

12 Figure 2: #99310 Temp. (oc) Time post-challenge (hr) 96 Figure 3: #41384 Temp (oc) Time post-challenge (hr) 11

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44